<DOC>
	<DOCNO>NCT01749891</DOCNO>
	<brief_summary>The general objective study evaluate safety efficacy ophthalmic intravitreal injection ALG-1001 human subject wet age-related macular degeneration ( Wet AMD ) . This study build upon safety efficacy result numerous animal study earlier Phase I Human Study end-stage diabetic macular edema patient .</brief_summary>
	<brief_title>A Safety And Efficacy Study Of ALG-1001 In Human Subjects With Wet Age-Related Macular Degeneration</brief_title>
	<detailed_description>The general objective study evaluate safety efficacy ophthalmic intravitreal injection ALG-1001 human subject wet age-related macular degeneration ( Wet AMD ) . This study build upon safety efficacy result numerous animal study earlier Phase I Human Study end-stage diabetic macular edema patient . The specific objective six-month study evaluate safety efficacy three monthly ophthalmic intravitreal injection ALG-1001 human subject Wet AMD , follow subject additional four month off-treatment . Three cohort establish part study design , utilizing three different dos .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>1 . Male female subject , 50 year age old . 2 . Active wet macular degeneration ( AMD ) . 3 . Subfoveal CNV ( choroidal neovascular membrane ) secondary AMD study eye less equal 12 MPS disc area . 4 . CNV great 50 % lesion area . 5 . CNV may classic , minimally classic , occult . 6 . For minimally classic occult lesion study eye , must demonstrate decrease BCVA ( best correct visual acuity ) must assess base clinical exploration , macular thickening , presence subretinal fluid hemorrhage , and/or OCT finding consistent CNV . 7 . Study eye BCVA 20/50 20/320 ETDRS ( Early Treatment Diabetic Retinopathy Study ) equivalent ( 65 letter 23 letter ) , opinion investigator primarily due Wet AMD . 8 . Decrease BCVA must assess base clinical exploration , macular thickening , and/or fluorescein angiography consistent CNV . 9 . IntraOcular Pressure ( IOP ) control , IOP â‰¤ 25 mm . 10 . Willing able return study visit . 11 . Able meet extensive postop evaluation regimen . 12 . Patient understand sign inform consent form . 13 . If subject female le 60 year old , negative pregnancy test screening window . 1 . Media opacities abnormality would preclude observation retina . 2 . Other retinal pathology would interfere patient 's vision . 3 . Presence cause CNV , include pathologic myopia , OHS ( ocular histoplasmosis syndrome ) , angioid streak , choroidal rupture multifocal choroiditis study eye . 4 . RPE ( retinal pigment epithelium ) rip tear study eye . 5 . Patients current prior retinal detachment , retinal tear , tractional detachment either eye . 6 . A history cataract surgery complications/vitreous loss study eye . 7 . A history penetrate ocular trauma study eye . 8 . Chronic recurrent uveitis . 9 . Has undergone vitrectomy ( anterior par plana ) study eye . 10 . Ongoing ocular infection inflammation either eye . 11 . A history intravitreal injection type study eye within last 45 day prior study enrollment . 12 . A history cataract surgery complications/vitreous loss study eye . 13 . Congenital malformation study eye . 14 . Mentally handicap . 15 . Pregnant nursing female . 16 . Currently participate clinical research study 17 . Contraindication study medication .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Age Related Wet Macular Degeneration</keyword>
</DOC>